HRP20050845A2 - Prostaglandin analogs as ep4 receptor antagonists - Google Patents

Prostaglandin analogs as ep4 receptor antagonists

Info

Publication number
HRP20050845A2
HRP20050845A2 HR20050845A HRP20050845A HRP20050845A2 HR P20050845 A2 HRP20050845 A2 HR P20050845A2 HR 20050845 A HR20050845 A HR 20050845A HR P20050845 A HRP20050845 A HR P20050845A HR P20050845 A2 HRP20050845 A2 HR P20050845A2
Authority
HR
Croatia
Prior art keywords
receptor antagonists
prostaglandin analogs
prostaglandin
glaucoma
agonists
Prior art date
Application number
HR20050845A
Other languages
English (en)
Croatian (hr)
Inventor
Billot Xavier
Colucci John
Yongxin Han
Wilson Marie-Claire
N. Young Robert
Original Assignee
Merck Frosst Canada Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Frosst Canada Ltd. filed Critical Merck Frosst Canada Ltd.
Publication of HRP20050845A2 publication Critical patent/HRP20050845A2/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C07D211/76—Oxygen atoms attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/06—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings
    • C07D265/08—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D265/10—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
HR20050845A 2003-03-26 2005-09-23 Prostaglandin analogs as ep4 receptor antagonists HRP20050845A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45770003P 2003-03-26 2003-03-26
PCT/CA2004/000471 WO2004085431A1 (en) 2003-03-26 2004-03-26 Prostaglandin analogs as ep4 receptor antagonists

Publications (1)

Publication Number Publication Date
HRP20050845A2 true HRP20050845A2 (en) 2006-05-31

Family

ID=33098243

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20050845A HRP20050845A2 (en) 2003-03-26 2005-09-23 Prostaglandin analogs as ep4 receptor antagonists

Country Status (22)

Country Link
US (4) US7053085B2 (zh)
EP (1) EP1613621B1 (zh)
JP (1) JP4866992B2 (zh)
KR (1) KR20060002873A (zh)
CN (1) CN1764659A (zh)
AR (1) AR040806A1 (zh)
AT (1) ATE474837T1 (zh)
BR (1) BRPI0408690A (zh)
CA (1) CA2519938C (zh)
CL (1) CL2004000655A1 (zh)
DE (1) DE602004028229D1 (zh)
EC (1) ECSP056037A (zh)
ES (1) ES2347434T3 (zh)
HR (1) HRP20050845A2 (zh)
IS (1) IS7999A (zh)
MA (1) MA27667A1 (zh)
MX (1) MXPA05010189A (zh)
NO (1) NO20054951L (zh)
PE (1) PE20050522A1 (zh)
RU (1) RU2005132930A (zh)
TW (1) TW200427670A (zh)
WO (2) WO2004085430A1 (zh)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7053085B2 (en) * 2003-03-26 2006-05-30 Merck & Co. Inc. EP4 receptor agonist, compositions and methods thereof
RU2311409C2 (ru) * 2003-01-10 2007-11-27 Ф.Хоффманн-Ля Рош Аг Производные 2-пиперидона в качестве агонистов простагландина
WO2004108215A1 (en) * 2003-06-06 2004-12-16 Allergan, Inc. Piperidinyl prostaglandin e analogs
US7326716B2 (en) 2003-06-06 2008-02-05 Allergan, Inc. Treatment of inflammatory bowel disease
US6977260B2 (en) 2004-01-22 2005-12-20 Allergan, Inc. Piperidinyl prostaglandin E analogs
US7179820B2 (en) 2003-06-06 2007-02-20 Allergan, Inc. Piperidinyl prostaglandin E analogs
CA2537119A1 (en) 2003-09-02 2005-03-10 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
CN1842335A (zh) 2003-09-04 2006-10-04 默克公司 用于治疗高眼压的眼用组合物
ATE425971T1 (de) 2003-09-04 2009-04-15 Merck & Co Inc Ophthalmische zusammensetzungen zur behandlung der okularen hypertonie
CA2571786A1 (en) 2004-07-02 2006-02-09 Allergan, Inc. Prostaglandin analogs
CN1988903A (zh) * 2004-07-20 2007-06-27 默克公司 用于治疗高眼压症的眼用组合物
JP2008518013A (ja) * 2004-10-26 2008-05-29 アラーガン、インコーポレイテッド プロスタグランジンｅｐ４アゴニストによる処置方法およびデリバリー方法
US7994195B2 (en) * 2004-11-04 2011-08-09 Allergan, Inc. Therapeutic substituted piperidone compounds
US7531533B2 (en) 2005-01-27 2009-05-12 Asahi Kasei Pharma Corporation 6-Membered heterocyclic compound and use thereof
JP5014978B2 (ja) * 2005-01-27 2012-08-29 旭化成ファーマ株式会社 ヘテロ６員環化合物及びその用途
JP2009502982A (ja) * 2005-08-03 2009-01-29 メルク フロスト カナダ リミテツド Ｅｐ４受容体アゴニスト、この組成物および方法
CA2616604A1 (en) * 2005-08-03 2007-02-08 Merck Frosst Canada Ltd. Ep4 receptor agonist, compositions and methods thereof
UY30121A1 (es) 2006-02-03 2007-08-31 Glaxo Group Ltd Nuevos compuestos
US7498447B2 (en) 2006-05-24 2009-03-03 Allergan, Inc. Therapeutic compounds
US7550448B2 (en) 2006-05-24 2009-06-23 Allergan, Inc. Therapeutic compounds
WO2008027340A2 (en) * 2006-08-30 2008-03-06 Merck & Co., Inc. Topical ophthalmic formulations
WO2008027341A2 (en) * 2006-08-30 2008-03-06 Merck & Co., Inc. Topical ophthalmic formulations
EP3824885A1 (en) 2006-10-20 2021-05-26 Children's Medical Center Corporation Method to enhance tissue regeneration
CN101168514B (zh) * 2006-10-26 2011-12-07 上海药明康德新药开发有限公司 光学活性α-氨基辛二酸酯和α-氨基辛二酸单酯的合成方法
EA015931B1 (ru) 2006-12-15 2011-12-30 Глэксо Груп Лимитед Бензамидные производные как агонисты ер-рецепторов
GB2446652A (en) * 2007-02-16 2008-08-20 Inion Ltd Osteogenic compounds
MX2009012043A (es) 2007-05-08 2010-02-18 Nat Univ Corp Hamamatsu Activador de celulas t citotoxicas que comprende agonista ep4.
MX2009013355A (es) * 2007-06-07 2010-02-22 Astellas Pharma Inc Compuesto de piridona.
GB0721611D0 (en) 2007-11-02 2007-12-12 Glaxo Group Ltd Novel compounds
CN101468985A (zh) * 2007-12-28 2009-07-01 中国人民解放军军事医学科学院毒物药物研究所 5-(3-芳杂环取代苯基)四氮唑类化合物及其抗hiv/aids的应用
US8633310B2 (en) * 2008-02-19 2014-01-21 Allergan, Inc. Therapeutic substituted lactams
US7964596B2 (en) 2008-03-07 2011-06-21 Allergan, Inc. Therapeutic compounds
KR20120093955A (ko) 2009-10-14 2012-08-23 젬머스 파마 인코포레이티드 바이러스 감염에 대한 병용 요법 치료
CA2738045C (en) * 2010-05-28 2019-02-19 Simon Fraser University Conjugate compounds, methods of making same, and uses thereof
US20160184387A1 (en) 2013-08-09 2016-06-30 Dominique Charmot Compounds and methods for inhibiting phosphate transport
US9650414B1 (en) 2014-05-30 2017-05-16 Simon Fraser University Dual-action EP4 agonist—bisphosphonate conjugates and uses thereof
CA2988523A1 (en) 2015-06-12 2016-12-15 Simon Fraser University Amide-linked ep4 agonist-bisphosphonate compounds and uses thereof
WO2017126635A1 (ja) * 2016-01-22 2017-07-27 武田薬品工業株式会社 複素環化合物およびその用途
PL3733665T3 (pl) 2017-12-25 2023-02-06 Asahi Kasei Pharma Corporation Związki zawierające ugrupowanie 2-okso-1,3,4-tiadiazynan-3-ylowe mające aktywność agonisty receptora EP4
WO2020237096A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Combination for lowering serum phosphate in a patient
CN111269193B (zh) * 2020-04-02 2022-05-24 湖南海利常德农药化工有限公司 一种苯并[e][1,3]噁嗪-2,4-二酮的制备方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1524818A (en) 1974-11-29 1978-09-13 Beecham Group Ltd 12-azaprostaglandins
US4177346A (en) 1976-08-06 1979-12-04 Pfizer Inc. 1,5-Disubstituted-2-pyrrolidones
EP0008186A1 (en) 1978-08-08 1980-02-20 Beecham Group Plc Cyclic diamides, a process for their preparation and their pharmaceutical compositions
FR2534580A1 (fr) 1982-10-13 1984-04-20 Synthelabo Derives de phenyl-1 piperidino-2 propanol, leur preparation, et medicaments qui les contiennent
US5151444B1 (en) 1987-09-18 1999-07-06 R Tech Ueno Ltd Ocular hypotensive agents
US4960771A (en) * 1988-07-12 1990-10-02 Rajadhyaksha Vithal J Oxazolidinone penetration enhancing compounds
ATE420857T1 (de) 1988-09-06 2009-01-15 Pfizer Health Ab Prostaglandin-derivate zur behandlung von glaukom und ocularer hypertension
US5296504A (en) 1988-09-06 1994-03-22 Kabi Pharmacia Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5352708A (en) 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5922773A (en) 1992-12-04 1999-07-13 The Children's Medical Center Corp. Glaucoma treatment
US5510383A (en) 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
JPH10265454A (ja) 1997-01-27 1998-10-06 Ono Pharmaceut Co Ltd ３，７−ジチアプロスタン酸誘導体、それらの製造方法およびそれらを有効成分として含有する薬剤
US6043275A (en) 1998-04-16 2000-03-28 Ono Pharmaceutical Co., Ltd. 3,7-dithiaprostanoic acid derivative
WO2000015608A1 (en) 1998-09-14 2000-03-23 Ono Pharmaceutical Co., Ltd. φ-SUBSTITUTED PHENYL-PROSTAGLANDIN E DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT
WO2000021542A1 (en) 1998-10-15 2000-04-20 Merck & Co., Inc. Methods for stimulating bone formation
WO2000038663A2 (en) 1998-12-24 2000-07-06 Alcon Laboratories, Inc. Ep4 receptor agonists for treatment of dry eye
MXPA02006322A (es) 1999-12-22 2002-12-13 Pfizer Prod Inc Agonistas selectivos del receptor ep4 en el tratamiento de la osteoporosis.
CN1450994A (zh) 2000-03-17 2003-10-22 爱尔康公司 用于治疗青光眼的6－羟基－吲唑衍生物
CA2374731A1 (en) 2000-03-31 2001-10-04 Toray Industries, Inc. Agent for modulating growth or generation of hair
AU2001290250A1 (en) 2000-09-21 2002-04-02 Ono Pharmaceutical Co. Ltd. Ep4 receptor agonists containing 8-azaprostaglandin derivatives as the active ingredient
DK1339678T3 (da) 2000-11-27 2008-02-04 Pfizer Prod Inc Selektive agonister til EP4-receptor til behandling af osteoporose
JP2004530647A (ja) 2001-01-30 2004-10-07 メルク　エンド　カムパニー　インコーポレーテッド 高眼圧治療用眼薬組成物
EP1373545A4 (en) 2001-03-22 2005-07-20 Merck & Co Inc MICE WITH MCH1R LACK
US20040204590A1 (en) 2001-12-03 2004-10-14 Ogidigben Miller J. Ep4 receptor agonist, compositions and methods thereof
AU2002346562A1 (en) 2001-12-03 2003-06-17 Merck & Co., Inc. Method for treating ocular hypertension
EP1515721A4 (en) 2002-06-14 2006-07-26 Merck & Co Inc OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION
EP1515974A4 (en) 2002-06-17 2007-02-28 Merck & Co Inc NOVEL MAXI K CHANNEL BLOCKERS, METHODS OF USE, AND METHODS OF MANUFACTURING THE SAME
EP1515730A4 (en) 2002-06-17 2005-07-20 Merck & Co Inc NEW MAXI K CHANNEL INHIBITORS, METHODS OF USE, AND METHOD OF MANUFACTURING THE SAME
US7053085B2 (en) * 2003-03-26 2006-05-30 Merck & Co. Inc. EP4 receptor agonist, compositions and methods thereof
RU2311409C2 (ru) 2003-01-10 2007-11-27 Ф.Хоффманн-Ля Рош Аг Производные 2-пиперидона в качестве агонистов простагландина
US6747037B1 (en) 2003-06-06 2004-06-08 Allergan, Inc. Piperidinyl prostaglandin E analogs

Also Published As

Publication number Publication date
US20110237511A1 (en) 2011-09-29
BRPI0408690A (pt) 2006-03-28
US20050227969A1 (en) 2005-10-13
RU2005132930A (ru) 2006-02-10
CN1764659A (zh) 2006-04-26
ATE474837T1 (de) 2010-08-15
US7053085B2 (en) 2006-05-30
JP4866992B2 (ja) 2012-02-01
WO2004085430A1 (en) 2004-10-07
USRE42562E1 (en) 2011-07-19
PE20050522A1 (es) 2005-07-06
CA2519938A1 (en) 2004-10-07
AU2004224261A1 (en) 2004-10-07
CA2519938C (en) 2010-11-30
AR040806A1 (es) 2005-04-20
US7238710B2 (en) 2007-07-03
DE602004028229D1 (de) 2010-09-02
ES2347434T3 (es) 2010-10-29
US20040198701A1 (en) 2004-10-07
EP1613621B1 (en) 2010-07-21
MA27667A1 (fr) 2005-12-01
NO20054951L (no) 2005-12-22
KR20060002873A (ko) 2006-01-09
JP2006520758A (ja) 2006-09-14
WO2004085431A1 (en) 2004-10-07
CL2004000655A1 (es) 2005-01-21
IS7999A (is) 2005-08-25
EP1613621A1 (en) 2006-01-11
MXPA05010189A (es) 2006-02-22
ECSP056037A (es) 2006-01-27
NO20054951D0 (no) 2005-10-25
TW200427670A (en) 2004-12-16

Similar Documents

Publication Publication Date Title
HRP20050845A2 (en) Prostaglandin analogs as ep4 receptor antagonists
ATE487514T1 (de) 1,5-disubstituierte pyrrolid-2-on-derivate zur verwendung als ep4 rezeptor agonisten zur behandlung von augenkrankheiten wie z.b. glaukom
TNSN01166A1 (fr) Composes agonistes selectifs des recepteurs ep4 et compositions les contenant.
RS51516B (en) ADDITIONAL HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTAGONISTS OF METABOTROPIC GLUTAMATE RECEPTORS
DZ3402A1 (fr) Cyclopentanoindoles, compositions contenant ces composes et methodes de traitement
WO2003047513A3 (en) Method for treating ocular hypertension
PE20080053A1 (es) Composiciones oftalmicas de alcaftadina
BR0108395A (pt) Derivados de pirrolopirimidinona, processos de preparação e uso
GEP20094780B (en) Prostaglandin nitrooxyderivatives
DK1576970T3 (da) Intraluminal indretning med en coating, der indeholder et terapeutisk middel
UA83311C2 (en) 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
NI200700056A (es) Nuevos derivados de sulfamidas de heteroaril benzo-fundido útiles como agentes anticonvulsivos
CU23208A3 (es) Oxazolidinonas sustituidas y su uso en el campo de la coagulacion sanguinea
PE20081755A1 (es) Nuevas 2-aminooxazolinas como ligandos taar1
MA28680B1 (fr) 3-aminocyclopentanecarboxamides utiles comme modulateurs de récepteurs de chimiokines
MX2010007295A (es) Composiciones acuosas estables de ciclosporina.
PE20001600A1 (es) Derivados de 1,4-diazabiciclo (3.3.2) nonan-4-carboxilatos y carboxamidas, su preparacion y su aplicacion en terapeutica
NO20052751L (no) Oftalmisk preparat for behandling av okulaer hypertensjon.
DE69924254D1 (de) Verwendung von a3-adenosine antagonisten zur herstellung eines arzneimittels zur senkung des augeninnendrucks
UY29802A1 (es) Análogos de la feniletilamina y su uso en el tratamiento del glaucoma
MA30077B1 (fr) 3-aminocyclopentanecarboxamides servant de modulateurs de recepteurs de chimiokines
AR069349A1 (es) Uso de antagonistas del receptor trpv1 para el tratamiento del ojo y del dolor ocular
BRPI0406879A (pt) Dispositivo de liberação sustentada e método para a liberação ocular de agentes adrenérgicos
WO2003047417A3 (en) Ep4 receptor agonist, compositions and methods thereof
AR036199A1 (es) Metodos y composiciones para el tratamiento de enfermedades oftalmicas

Legal Events

Date Code Title Description
ODRP Renewal fee for the maintenance of a patent

Payment date: 20060313

Year of fee payment: 3

A1OB Publication of a patent application
OBST Application withdrawn